Medicass Biotechnologies, founded in the beginning of this new century, are primarily focused on 1) supply and contracted manufacturing of cGMP APIs, pharmaceutical intermediates, and nutraceutical raw materials, and 2) Discovery and development of TCM-based and value-added new pharmaceutical products, especially originated from Chinese medicinal herbs Astragalus membranaceus, Triptergium wilfordii,, and Salvia miltiorrhiza.

       Medicass Biotechnologies possesses an experienced team in cGMP manufacturing of APIs and pharmaceutical intermediates as well as in process development and scale-up, particularly starting from Chinese medicinal plants. Our cGMP manufacturing and QC analytical facilities located in Beijing and in Guiling (Guilin Sanleng Biotech) have been audited by pharmaceutical companies from USA, Canada, Europe, and Hong Kong in addition to China SFDA in last 5 years. Currently we are holding a GMP Certificate issued by China SFDA in 2004.

       Medicass, led by a group of world-class scientists, has a broad and innovative proprietary technology platform that enables us to discover, and to develop TCM-derived and value-added novel therapeutics, including both SCEs and large molecules mainly for anti-tumor and immune-regulation. Our state of the art R & D and analytical facilities have been well established in Beijing, supporting and ensuring our manufacturing and research activities.